Articles tagged "Kidney transplantation"

2018 American Transplant Congress
The Impact of Early versus Late Clinical Outcomes on Disparities in African-American Kidney Transplant Recipients
D. Taber, J. Fleming, Z. Su, P. Mauldin, J. McGillicuddy, S. Nadig, V. Rohan, P. Baliga, D. Dubay.
MUSC, Charleston, SC.
Background: It is important to better understand the impact of early and late clinical events on disparities in African-American (AA) kidney transplant (KTX), which will…
2018 American Transplant Congress
Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection – A Double-Blind Randomized Placebo-Controlled Trial (BORTEJECT Study)
F. Eskandary,¹ H. Regele,² G. Bond,¹ N. Kozakowski,² M. Wahrmann,¹ L. Hidalgo,³ H. Haslacher,⁴ C. Kaltenecker,¹ M-.B. Aretin,⁵ R. Oberbauer,¹ J. Reeve,⁶ P. Halloran,⁶ G. Böhmig.¹
¹Nephrology and Dialysis, Medical University Vienna, Viena, Austria; ²Institute of Clinical Pathology, Medical University Vienna, Vienna, Austria; ³Department of Laboratory Medicine and Pathology, University of Alberta, Edmonton, AB, Canada; ⁴Department of Laboratory Medicine, Medical University Vienna, Vienna, Austria; ⁵Pharmacy Department, General Hospital Vienna, AKH, Vienna, Austria; ⁶Alberta Transplant Applied Genomics Centre, University of Alberta, Edmonton, AB, Canada.
Background. Antibody-mediated rejection (ABMR) is a leading cause of long-term kidney transplant loss. Optimal treatment of late ABMR is unclear, and our current knowledge is…
2018 American Transplant Congress
Validation of a Transplant Knowledge Quiz and Its Impact on Outcomes in Kidney Transplant Recipients
H. Corbo, N. Patel, N. Pilch, V. Rohan, J. Fleming, T. Harrison, J. Hardcopf, B. O'Brien, C. Perez, P. Baliga, H. Meadows, D. Taber.
Medical University of South Carolina, Charleston.
The aim of this study is to determine if transplant quiz scores given prior to discharge were predictive of known patient risk factors and if…
2018 American Transplant Congress
Impact of Antecedent Malignancy on Kidney Transplant Outcomes: Patient, Graft, and Cancer-Free Survival
O. Serrano,¹ S. Mongin,² D. Berglund,¹ D. Vock,³ S. Chinnakotla,¹ T. Dunn,¹ E. Finger,¹ R. Kandaswamy,¹ T. Pruett,¹ A. Matas.¹
¹Surgery, University of Minnesota, Minneapolis, MN; ²Biostatistical Design and Analysis Center, Clinical and Translational Science Institute, Minneapolis, MN; ³Biostatistics, University of Minnesota, Minneapolis, MN.
OBJECTIVE: Non-skin pretransplant malignancy (NSPTM) has historically been considered a relative contraindication to kidney transplantation (KT). In addition to the conventional risk factors for cancer,…
2018 American Transplant Congress
Factor Analysis (FA) Identifies 5 Major Axes of Kidney Transplant Biopsy (KTxBx) Pathology
L. Hunsicker,¹ J. Grande,² J. Cecka,³ A. Matas,⁴ The DeKaf Consortium.
¹Int. Med., U. Iowa, Iowa City, IA; ²Pathology, Mayo Clinic, Rochester, MN; ³Immunogenetics, UCLA, Los Angeles, CA; ⁴Surgery, U. Minnesota, Minneapolis, MN.
Definitions for acute rejection (ACR) and antibody mediated rejection (AMR) in KTxBx exist, but no data driven methods exist for quantitative analysis of all Banff,…
2018 American Transplant Congress
Long Term Renal and Patient Risks for Living Kidney Donors
Y. Kim, M. Yu, Y. Kim, H. Lee.
Division of Nephrology, Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea.
Purpose:Recent studies have issued that living kidney donor (LKD) might be exposed to higher risk for end-stage renal disease (ESRD) and death, compared with healthy…
2018 American Transplant Congress
Cost Effectiveness of Hepatitis C Positive Donor Kidney Transplantation for Hepatitis C Negative Recipients with Concomitant Direct-Acting Anti-Viral Therapy
G. Gupta, Y. Zhang, H. Kale, N. Carroll, R. Sterling.
Virginia Commonwealth University, Richmond.
Background: The development of direct acting antiviral (DAA) therapy for hepatitis C virus (HCV) could allow for safe and effective treatment following renal transplantation (RT).…
2018 American Transplant Congress
Early Steroid Withdrawal and Kidney Transplant Outcomes for Recipients with Delayed Graft Function
S. Bae, A. Massie, X. Luo, J. Garonzik Wang, D. Segev.
Johns Hopkins, Baltimore, MD.
Current guidelines suggest early steroid withdrawal (ESW) regimen for kidney transplant (KT) recipients with low immunological risk. Delayed graft function (DGF) is a risk factor…
2018 American Transplant Congress
What Deceased Donors Do KPD Candidates Accept?
A. Toll,¹ R. Leishman,¹ V. Casingal,² M. Aeder,³ T. Sandholm,⁴ N. Turgeon.⁵
¹UNOS, Richmond, VA; ²Carolinas HealthCare Sys, Charlotte, NC; ³Univ Hosp Med Ctr, Cleveland, OH; ⁴Carnegie Mellon Univ, Pittsburgh, PA; ⁵Emory Univ, Atlanta, GA.
Background: Possible utilization of deceased donors (DDs) to initiate KPD chains has been of interest to the transplant community. OPTN KPD candidates are required to…
2018 American Transplant Congress
Genome Wide Non-HLA Alloimmunity Contributes to Graft Loss after Kidney Transplantation
R. Reindl-Schwaighofer, A. Heinzel, A. Kainz, K. Jelencsics, O. Viklicky, G. Böhmig, G. Fischer, B. Keating, R. Oberbauer.
Division of Nephrology and Dialysis, Medical University of Vienna, Vienna, Austria; Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic; Transplant Institute, University of Pennsylvania, Philadelphia, PA.
BackgroundChronic rejection is the main cause of renal transplant loss after the first year and has mostly been attributed to alloimmune responses against human leukocyte…